🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Bladder and Bowel Dysfunction

Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD) NCT06091566NA3 sites📍 Aarhus📍 Herlev📍 Odense InnoCon Medical · Tests: UCon-Bar IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA NCT05754190n/a1 site📍 Providence Brown University · Tests: SOMA pain manager smartphone application Cancer Loyalty Card Study 2 (CLOCS-2) NCT06447064n/a1 site📍 London Imperial College London · Tests: Cases & Controls Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) NCT06116019n/a1 site📍 Berlin Charite University, Berlin, Germany · Tests: Online adaptive radiation therapy PET-imaging of Two Vartumabs in Patients With Solid Tumors NCT06645808EARLY Phase 11 site📍 Groningen Var2 Pharmaceuticals · Tests: 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women NCT06904365n/a1 site📍 St Louis Washington University School of Medicine · Tests: HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0 Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) NCT04498767NA13 sites📍 Anderlecht📍 Ghent📍 Wilrijk European Organisation for Research and Treatment of Cancer … · Tests: Stereotactic body radiotherapy, Palliative RT Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) NCT06101277NA1 site📍 Sacramento University of California, Davis · Tests: Ablative local therapy The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study NCT04075305n/a18 sites📍 Pittsburgh📍 Houston📍 Milwaukee UMC Utrecht · Tests: Radiation therapy Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) NCT07327489n/a8 sites📍 Fort Smith📍 Frederick📍 Springfield Elephas · Tests: Biopsy The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas NCT07285044Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cancer Therapeutic Procedure, Cancer Therapeutic Procedure, Questionnaire Administration Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab Improving Care for Rural Patients With Solid Tumors NCT04916990NA14 sites📍 Aurora📍 Colorado Springs📍 Colorado Springs University of Colorado, Denver · Tests: CARES Intervention A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors NCT07030257Phase 1, Phase 213 sites📍 Denver📍 Orlando📍 Grand Rapids Tasca Therapeutics · Tests: CP-383 ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444n/a57 sites📍 Birmingham📍 Chandler📍 Hot Springs Guardant Health, Inc. · Tests: Guardant Reveal Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051n/a1 site📍 Austin Natera, Inc. A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion Telehealth Intervention for Ostomy Self-Management NCT06528990Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Telehealth Intervention, Standard of care Effects of Sacral and Tibial Stimulation on Bladder Function in Subacute Suprasacral Spinal Cord Injury NCT07343583NA1 site📍 Ankara Ankara City Hospital Bilkent · Tests: Transcutaneous Tibial Nerve Stimulation, Transcutaneous Sacral Nerve Stimulation Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury NCT05369520NA2 sites📍 Vancouver📍 Vancouver University of British Columbia · Tests: TESCoN or SCONE device - Thoracic stimulation, TESCoN or SCONE device - Lumbosacral stimulation Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery NCT06926374NA1 site📍 Hong Kong Chinese University of Hong Kong · Tests: Robotic surgery using the Sentire Surgical System The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract NCT07077447n/a5 sites📍 Aarhus N📍 Herlev📍 København Ø Zealand University Hospital · Tests: Kidney sparing surgery for high-risk upper urinary tract urothelial carcinoma A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 Evaluation for NCI Surgery Branch Clinical Research Protocols NCT00001823n/a1 site📍 Bethesda National Cancer Institute (NCI) The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06760819Phase 254 sites📍 Birmingham📍 Duarte📍 Fort Myers Bayer · Tests: BAY2927088 Prehabilitation in High-risk Oncologic Surgery NCT07638410NA1 site📍 Philadelphia Fox Chase Cancer Center · Tests: Multidisciplinary Prehabilitation Program
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy